{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:03:14Z","timestamp":1787508194871,"version":"build-2736575974"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Enzalutamide, a second-generation androgen receptor inhibitor (SGARI) for prostate cancer, is associated with rare but severe pulmonary toxicities. While typically manifesting as drug-induced interstitial lung disease (DI-ILD), these agents can also trigger acute exacerbation or rapid progression of pre-existing interstitial lung abnormalities (ILA). We report the case of an 83-year-old man with baseline ILA and emphysema who had previously undergone a laparoscopic radical prostatectomy. He maintained stable respiratory symptoms on bicalutamide for four years but developed progressive dyspnea within one month of switching to enzalutamide for biochemical recurrence. However, a chest computed tomography (CT) scan was not performed promptly upon symptom deterioration. This missed opportunity for early radiologic evaluation resulted in a 10-month diagnostic delay. Following the immediate discontinuation of enzalutamide and the concurrent initiation of nintedanib, the patient achieved radiologic stability and demonstrated improved exercise tolerance at the 6-month follow-up. From the patient\u2019s perspective, the rapid progression of dyspnea was highly distressing, but he expressed significant relief and satisfaction with the improvement in his exercise tolerance following the medication adjustment. This clinical course highlights that prompt withdrawal of the offending agent is paramount, while phenotype-driven antifibrotic therapy may serve as a potential supportive intervention once irreversible fibrosis is established.<\/jats:p>","DOI":"10.3389\/fmed.2026.1861913","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:48:44Z","timestamp":1783403324000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Enzalutamide-associated acute exacerbation of interstitial lung abnormality: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Siji","family":"Meiduo","sequence":"first","affiliation":[{"name":"Southwest Medical University","place":["Luzhou, China"]},{"name":"The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Deng","sequence":"additional","affiliation":[{"name":"Southwest Medical University","place":["Luzhou, China"]},{"name":"The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulai","family":"Yuan","sequence":"additional","affiliation":[{"name":"The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Yang","sequence":"additional","affiliation":[{"name":"The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Lin","sequence":"additional","affiliation":[{"name":"The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhua","family":"Ao","sequence":"additional","affiliation":[{"name":"The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate Cancer","volume":"381","author":"Chi","year":"2019","journal-title":"New engl j med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.resinv.2021.05.006","article-title":"Apalutamide-induced severe interstitial lung disease: a report of two cases from Japan","volume":"59","author":"Kobe","year":"2021","journal-title":"Respir Investig"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"655605","DOI":"10.3389\/fphar.2021.655605","article-title":"Evaluation of potential complications of interstitial lung disease associated with antiandrogens using data from databases reporting spontaneous adverse effects","volume":"12","author":"Nawa","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bcp.15336","article-title":"Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration adverse event reporting system","volume":"89","author":"Wu","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/iju5.12428","article-title":"Editorial comment to interstitial lung disease induced by apalutamide therapy for castration-resistant prostate cancer: a report of a rare case","volume":"5","author":"Yuasa","year":"2022","journal-title":"IJU Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2102776","DOI":"10.1183\/13993003.02776-2021","article-title":"Drug-induced interstitial lung disease","volume":"60","author":"Spagnolo","year":"2022","journal-title":"Eur Respir J"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/s2213-2600(20)30168-5","article-title":"Interstitial lung abnormalities detected incidentally on CT: a position paper from the Fleischner society","volume":"8","author":"Hatabu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/resp.13682","article-title":"Acute exacerbations of fibrotic interstitial lung diseases","volume":"25","author":"Suzuki","year":"2020","journal-title":"Respirology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1183\/09031936.00080209","article-title":"Rituximab-induced lung disease: a systematic literature review","volume":"35","author":"Liot\u00e9","year":"2010","journal-title":"Eur Respir J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.3389\/fimmu.2020.01698","article-title":"Androgen and androgen receptors as regulators of monocyte and macrophage biology in the healthy and diseased lung","volume":"11","author":"Becerra-Diaz","year":"2020","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.4049\/jimmunol.1800352","article-title":"Androgen and androgen receptor as enhancers of M2 macrophage polarization in allergic lung inflammation","volume":"201","author":"Becerra-D\u00edaz","year":"2018","journal-title":"J Immunol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.mce.2009.12.022","article-title":"Androgen receptor and androgen-dependent gene expression in lung","volume":"317","author":"Mikkonen","year":"2010","journal-title":"Mol Cell Endocrinol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/er.2010-0031","article-title":"Sex differences and sex steroids in lung health and disease","volume":"33","author":"Townsend","year":"2012","journal-title":"Endocr Rev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/jcm7100356","article-title":"Drug-induced interstitial lung disease: a systematic review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J Clin Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","article-title":"Consensus statement for the diagnosis and treatment of drug-induced lung injuries","volume":"51","author":"Kubo","year":"2013","journal-title":"Respir Investig"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1900161","DOI":"10.1183\/13993003.00161-2019","article-title":"Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases","volume":"54","author":"Wollin","year":"2019","journal-title":"Eur Respir J"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00251-017-1007-5","article-title":"The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions","volume":"69","author":"Illing","year":"2017","journal-title":"Immunogenetics"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1861913\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:48:45Z","timestamp":1783403325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1861913\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":19,"alternative-id":["10.3389\/fmed.2026.1861913"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1861913","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"1861913"}}